BYD India Unveils its Luxury Electric Sedan BYD Seal & Launches BYD ATTO 3 Limited Edition at Auto Expo 2023
BYD, the global leading new energy vehicle (NEV) manufacturer, presented its new luxury model BYD Seal and the limited edition of BYD ATTO 3 in its iconic color Forest Green at the Indian Auto Expo 2023. BYD Seal, whose sales have exceeded 50,000 within 5 months in China, is planned to be launched in India by Q4 2023. As the All-New e6 and BYD ATTO 3 are already available in the local market, BYD Seal will be the third passenger EV released in India within two years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005445/en/
Speech by Sanjay Gopalakrishnan, Senior Vice President of Electric Passenger Vehicles, BYD India (Photo: Business Wire)
At the Auto Expo 2023, BYD’s display space is sectioned into 4 zones, which showcase not only its current and new vehicle products but also technological innovations that substantially enhance the performance and safety of vehicles. These newly-unveiled products and innovation displays echo the Indian-specific theme at the convention: Technological Innovations For A Better Life.
BYD SEAL
BYD Seal is one of BYD’s latest luxury sedans equipped with its renowned EV platform (e-Platform 3.0) and revolutionary ultra-safe Blade Battery. Also, it is the first vehicle equipped with CTB (cell to body) technology, substantially upgrading the vehicle’s safety, stability, and handling, giving the vehicle an overall finer performance.
CTB-supported BYD Seal can withstand the 50-ton heavy-duty truck rolling test. Via the integration of battery and body, the torsional stiffness of the whole vehicle has doubled to above 40,500 N.m/°. The safety of the interior structure of the vehicle is increased by 50% for the front impact and by 45% for the side impact. Also, as CTB technology makes it possible for BYD Seal to have an ideal 50:50 axle load distribution, the vehicle passed the moose test at a record speed of 83.5km/h. With its low-lying design, the aero drag coefficient reached as low as 0.219cd, helping BYD Seal hit 100 km/h in 3.8 seconds. The model also has an ultra-long range of up to 700 km on a single charge, reducing the range anxiety of EVs.
BYD ATTO 3 Limited Edition
At the event, the Limited Edition of BYD ATTO 3 in the exclusive color of Forest Green, also adopts the e-Platform 3.0 and the ultra-safe Blade Battery. Only 1,200 units of this Limited Edition will be available in India at Rs. 34.49 lakhs (ex-showroom).
BYD ATTO 3, with an NEDC-certified range of 480 km and ARAI test range of 521 km, was launched in India in November 2022 for Rs. 33.99 lakhs and garnered 1,500 bookings to date, gaining good traction among customers. BYD ATTO 3 received a five-star safety rating from Euro NCAP, Europe’s leading independent safety assessment program. The E-SUV boasts an 8-year or 1.6 lakh kilometer (whichever comes earlier) warranty for the battery and a similar 8-year or 1.5 lakh kilometer warranty for the motor and motor controller. Besides, BYD offers a 6-year or 1.5 lakh kilometer basic warranty.
Sanjay Gopalakrishnan, Senior Vice President of Electric Passenger Vehicles of BYD India, said: “The Indian Auto Expo is an extremely significant platform for us, and we are pleased to be able to showcase our products and technologies through our technological innovations for a better life. With the unveiling of the electric luxury sedan BYD Seal, the launch of the Limited Edition of BYD ATTO 3, and the display of the Blade Battery, e-Platform 3.0, we resonate our commitment to contribute to the growth of the Indian electric vehicle segment with EV technologies.”
Within a year, BYD has expanded its network to 24 showrooms across 21 cities in India and will double the presence to 53 showrooms within 2023. “Next year, we plan to sell 15,000 units of BYD ATTO 3 and All-New e6 with a long-term vision to take up 40% of the Indian EV market by 2030. The bookings of BYD ATTO 3 have been encouraging, and we are all set to start the first deliveries from January 2023,” added Mr. Gopalakrishnan.
In 2022, BYD's cumulative sales of passenger vehicles were over 1.86 million units, a year-on-year increase of 155.1%. So far, BYD has sold more than 3.37 million new energy vehicles. With its expanding global presence, BYD is working towards its initiative of “Cool the Earth by 1 °C.”
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, the DM-i and DM-p hybrid technology, the e-Platform 3.0, and the CTB technology. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on the EV shift and has remained top of new energy passenger vehicle sales in China for 9 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005445/en/
Contact information
Asia-Pacific: Mia Gu, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com
tel: +56 9 96443906
Brazil: Adalberto Maluf, adalberto.maluf@byd.com tel: +19 3514 2554
Africa: Nikki Li, li.namin@byd.com tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 09:23:00 EET | Press release
Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline infusion preparation, reduce healthcare professionals’ workload, and support hospital operational efficiency.3 The Remsima™ IV liquid formulation is approved in the EU for all indications of IV infliximab, matching the approved uses of all existing IV infliximab powder formulations, including rheumatoid arthritis (RA), adult and pediatric Crohn’s disease (CD), ulcerative colitis (UC), pediatric UC, ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis (PsO).1 The comparability between lyophilized powder formulation and the liquid formulation of IV infliximab has been established through comprehensive chemistry, manufacturing, and controls data.2 The stability of the liquid formulation of I
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 05:35:00 EET | Press release
Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through its partners by the end of October 2025, marking a threefold increase compared to the same period in 2024, with MSMEs among the key segments driving this growth. International Finance Corporation estimates a US$8 trillion financing gap for MSMEs in emerging markets and developing economies. With global platforms, from e-commerce to food delivery, entering emerging markets and local platforms in these markets continue to scale, many are looking to offer tailored credit services to better support MSMEs operating on their ecosystems. Doin
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 05:00:00 EET | Press release
Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in real-time global treasury management. It has already supported a successful H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom